Pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) (NSEIFSC:DRREDDY), on Tuesday introduced Versavo (bevacizumab) in the UK for treating various cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, and metastatic breast cancer.

Versavo, Dr. Reddy's first biosimilar product launched in the UK, is available in 100mg and 400mg single use vials.

Having debuted in India in 2019, Versavo was subsequently rolled out in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same name, while in Colombia, it was introduced under the brand name Persivia.